Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 486.0% in June

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 54,009 shares, a growth of 486.0% from the May 31st total of 9,216 shares. Based on an average daily volume of 148,319 shares, the short-interest ratio is currently 0.4 days. Approximately 1.0% of the shares of the company are sold short.

Alterity Therapeutics Trading Down 0.1%

ATHE stock traded down $0.01 during trading on Friday, reaching $4.89. The company’s stock had a trading volume of 23,412 shares, compared to its average volume of 101,223. The company’s fifty day moving average is $4.45 and its 200-day moving average is $3.75. Alterity Therapeutics has a 1 year low of $4.14 and a 1 year high of $350.00.

Analyst Ratings Changes

Several research analysts have recently commented on the company. LADENBURG THALM/SH SH assumed coverage on Alterity Therapeutics in a research note on Tuesday, June 16th. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Monday, April 20th. Finally, Zacks Research upgraded shares of Alterity Therapeutics to a “hold” rating in a research note on Wednesday, June 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alterity Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Trading of Alterity Therapeutics

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics at the end of the most recent reporting period. Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.